

NSW Cancer Research Education

The PREDICT Program

Individualising drug dosing in cancer to improve efficacy and safety

Statewide Seminar Series 2023
Tuesday 16 May, 12.30 - 1.30 pm



**Professor
Jennifer Martin**

Chair of Clinical Pharmacology
School of Medicine and Public Health
University of Newcastle



**Professor
Nikola Bowden**

School of Medicine and Public Health
University of Newcastle
Chief Investigator, NSW Regional
Cancer Research Network

16
MAY
2023



12:30 – 1:30
PM PM



**Online
Webinar**

REGISTER NOW

The Research Capacity Building Grants are supported by the Cancer Institute NSW



Cancer
Clinical Academic Group

Session Information

The **PREDICT** program, funded by Cancer Council NSW, aims to develop a personalised chemotherapy dosing system for cancer patients to improve quality of life, reduce side effects and increase chance of survival.

Current chemotherapy dosing is imprecise and not personalised. It is estimated that 20-30% of patients receiving chemotherapy will receive a dose that is too high for them, and 20-30% will receive a dose lower than what is needed for optimal effectiveness. By monitoring chemotherapy levels early in treatment, clinicians will be able to adjust doses to achieve the ideal blood level. This will lead to direct and significant benefits for patients across wide population groups including enabling greater accessibility for rural and remote patients.

Speaker



Professor Jennifer Martin is the Chair of the discipline of Clinical Pharmacology in the School of Medicine and Public Health at the University of Newcastle. She is a clinical pharmacologist and physician and holds a PhD from Monash University.

Working in the Hunter New England Local Health District, Jennifer leads a team of pharmacy and medicine experts together with pharmacoepidemiologists and pharmacoeconomists, who work across a number of areas including cancer.

Most often centering on therapeutic drugs, the team look at everything from the design and development of drugs, to the clinical trials process, through to the post-marketing phase, where data is collected on how effective those drugs are in practice, and any side effects they might have.

Facilitator



Professor Nikola Bowden is co-Director of the University of Newcastle Centre for Drug Repurposing and Medicines Research and leads the DNA Repair Group. She is also Chief Investigator of the NSW Regional Cancer Research Network. Her research has the overall aim of delivering personalised diagnosis and treatment to patients with cancer, with a more focused interest in investigating DNA repair and drug repurposing for melanoma and ovarian cancer.